GASTROESOPHAGEAL JUNCTION CANCER
Clinical trials for GASTROESOPHAGEAL JUNCTION CANCER explained in plain language.
Never miss a new study
Get alerted when new GASTROESOPHAGEAL JUNCTION CANCER trials appear
Sign up with your email to follow new studies for GASTROESOPHAGEAL JUNCTION CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for stomach cancer patients: drug combo tested before and after surgery
Disease control CompletedThis study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy improves outcomes for Chinese adults with stomach or gastroesophageal junction cancer. The treatment was given both before surgery (to shrink tumors) and after surgery (to prevent recur…
Matched conditions: GASTROESOPHAGEAL JUNCTION CANCER
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
Major trial tests drug combo to stop stomach Cancer's return
Disease control CompletedThis large, completed Phase 3 trial tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy, given both before and after surgery, works better than chemotherapy alone for people with certain stomach cancers. The goal was to see if the combination helps…
Matched conditions: GASTROESOPHAGEAL JUNCTION CANCER
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
Real-World cancer treatment data revealed
Knowledge-focused CompletedThis study looked back at medical records to understand how well the drug nivolumab worked in real-world practice for 260 patients in China with advanced stomach cancer. It did not test a new treatment but collected information on how long the cancer was controlled and how patien…
Matched conditions: GASTROESOPHAGEAL JUNCTION CANCER
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:27 UTC